Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. IBIO
stocks logo

IBIO

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q2
FY2026Q3
FY2026Q4
25.00K
-87.5%
-0.093
-80.56%
--
--
-0.057
-88.43%
--
--
-0.067
-79.17%
Estimates Revision
The market is revising Upward the revenue expectations for iBio, Inc. (IBIO) for FY2026, with the revenue forecasts being adjusted by 80% over the past three months. During the same period, the stock price has changed by 53.29%.
Revenue Estimates for FY2026
Revise Upward
up Image
+80%
In Past 3 Month
EPS Estimates for FY2026
Revise Downward
down Image
-18.57%
In Past 3 Month
Stock Price
Go Up
up Image
+53.29%
In Past 3 Month
Wall Street analysts forecast IBIO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IBIO is 3.90 USD with a low forecast of 1.60 USD and a high forecast of 6.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
Wall Street analysts forecast IBIO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IBIO is 3.90 USD with a low forecast of 1.60 USD and a high forecast of 6.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.280
sliders
Low
1.60
Averages
3.90
High
6.00
Current: 1.280
sliders
Low
1.60
Averages
3.90
High
6.00
Oppenheimer
Jay Olson
Outperform
maintain
$5 -> $6
2025-10-30
Reason
Oppenheimer
Jay Olson
Price Target
$5 -> $6
2025-10-30
maintain
Outperform
Reason
Oppenheimer analyst Jay Olson raised the firm's price target on iBio to $6 from $5 and keeps an Outperform rating on the shares. The firm notes shares were up 8% vs. flat XBI, basking in well-deserved attention for IBIO-610 following updates from WVE's INHBE-targeting siRNA WVE-007. In its Phase 1 INLIGHT trial, WVE-007 elicited up to about 85% activin E reduction, surpassing the preclinical 70% activin E reduction threshold for potential 6-month weight loss comparable to semaglutide.
Oppenheimer
Oppenheimer
Outperform
maintain
$5 -> $6
2025-10-29
Reason
Oppenheimer
Oppenheimer
Price Target
$5 -> $6
2025-10-29
maintain
Outperform
Reason
Oppenheimer raised the firm's price target on iBio (IBIO) to $6 from $5 and keeps an Outperform rating on the shares, calling attention for IBIO-610 following updates from Wave Life Sciences' (WVE) WVE-007 "well-deserved." Wave's initial Phase 1 INLIGHT efficacy and safety readout this quarter could provide mechanistic validation for iBio's '601 and drive additional upside, the analyst tells investors.
Oppenheimer
Outperform
initiated
$5
2025-10-20
Reason
Oppenheimer
Price Target
$5
2025-10-20
initiated
Outperform
Reason
Oppenheimer initiated coverage of iBio with an Outperform rating and $5 price target, citing "optimism" for lead asset IBIO-610 to address key challenges in treating the growing obesity market. Preclinical data validate the potential of '610 to drive both fat loss and lean mass preservation, supporting "a highly differentiated and complementary profile," says the analyst, who views the drug as "an under-the-radar" next-generations approach that "could command strategic interest."
Leerink
Roanna Ruiz
Outperform
initiated
$2
2025-10-17
Reason
Leerink
Roanna Ruiz
Price Target
$2
2025-10-17
initiated
Outperform
Reason
Leerink analyst Roanna Ruiz initiated coverage of iBio with an Outperform rating and $2 price target. The firm argues that lead obesity asset IBIO-610 represents a preclinically validated, first-in-class antibody opportunity that could address the safety and durability limitations of RNA-based competitors. Following the recent $50M public offering, iBio should maintain liquidity through all pre-IND and IND catalysts, with Series G and H warrants providing up to an additional $50M in contingent capital tied to IND milestones, Leerink adds. This structure should support a self-funding runway through the second half of 2026, aligning with the expected IND filings for IBIO-610 and IBIO-600 by year-end 2026. Further, the firm believes iBio's proprietary AI/ML-driven antibody discovery and engineering platform should provide enhanced scalability and speed to identify and optimize novel biologics.
LUCID CAPITAL MARKETS
Dev Prasad
Strong Buy
Initiates
$6
2024-12-17
Reason
LUCID CAPITAL MARKETS
Dev Prasad
Price Target
$6
2024-12-17
Initiates
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for iBio Inc (IBIO.A) is -4.04, compared to its 5-year average forward P/E of -4.10. For a more detailed relative valuation and DCF analysis to assess iBio Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-4.10
Current PE
-4.04
Overvalued PE
3.21
Undervalued PE
-11.42

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
84.58
Current PS
0.00
Overvalued PS
190.64
Undervalued PS
-21.48
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

IBIO News & Events

Events Timeline

(ET)
2025-11-12
16:14:33
iBio Announces Q1 Earnings Per Share of 11 Cents, Exceeding Consensus Estimate of 7 Cents
select
2025-10-30 (ET)
2025-10-30
07:15:52
iBio Reveals New Preclinical Findings from NHP Study of IBIO-1610
select
2025-09-05 (ET)
2025-09-05
07:31:36
iBio Announces FY25 EPS of $1.75 Compared to ($6.50) in the Previous Year
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
10-30Newsfilter
iBio Reveals Promising Non-Human Primate Data for IBIO-610, an Activin E Antibody with Significant Potential for Targeted Weight Loss and Maintenance

  • IBIO-610 Overview: iBio, Inc. has announced promising preclinical data for IBIO-610, a potential first-in-class Activin E antibody, showing significant fat-selective weight loss and prevention of weight regain in a diet-induced obesity mouse model.

  • Extended Half-Life Findings: New data from non-human primate studies indicates an extended half-life of 33.2 days, with a predicted human half-life of up to 100 days, suggesting the possibility of dosing only twice a year.

  • Therapeutic Potential: The unique mechanism of action of IBIO-610 may provide a more comprehensive treatment for obesity and cardiometabolic diseases, addressing gaps left by current GLP-1 therapies.

  • Presentation at ObesityWeek: The findings will be presented at ObesityWeek 2025, highlighting the potential of IBIO-610 to improve patient experience with less frequent dosing and reduced side effects compared to existing treatments.

[object Object]
Preview
1.0
10-23Newsfilter
iBio to Attend the 2nd Annual Healthcare Innovation Conference Hosted by Guggenheim

  • iBio's Conference Participation: iBio, Inc. will participate in the Guggenheim 2nd Annual Healthcare Innovation Conference from November 10–12, 2025, where CEO Martin Brenner will discuss the company's advancements in becoming a clinical-stage biotechnology firm and its obesity pipeline.

  • Focus on Obesity Treatments: During the conference, Dr. Brenner will highlight iBio's differentiated antibody programs aimed at complementing existing obesity therapies and creating long-term value through innovation.

  • One-on-One Meetings: CFO Felipe Duran will join Dr. Brenner for one-on-one meetings with attendees at the conference, providing further insights into the company's strategies and developments.

  • Company Overview: iBio is a biotech company utilizing AI and advanced computational biology to develop innovative biopharmaceuticals for various diseases, including obesity and cancer, with a mission to transform drug discovery and accelerate development timelines.

[object Object]
Preview
9.0
10-23NASDAQ.COM
VTYX, MEDP, INBX Surge in After-Hours Trading Following Important Announcements

  • Ventyx Biosciences Surge: Ventyx Biosciences' shares skyrocketed over 88% after positive Phase 2 trial results for its obesity and cardiovascular risk treatment, VTX3232.

  • Medpace Holdings Performance: Medpace Holdings saw an 18% increase in shares following better-than-expected Q3 results and an updated fiscal year 2025 guidance.

  • Inhibrx Biosciences Update: Inhibrx Biosciences' shares rose over 10% as the company announced a live webcast to present topline results from its ChonDRAgon study on ozekibart for chondrosarcoma.

  • Other Notable Movers: Several biotech stocks, including Acumen Pharmaceuticals and SCYNEXIS, experienced significant after-hours gains, reflecting a broader positive trend in the sector.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is iBio Inc (IBIO) stock price today?

The current price of IBIO is 1.28 USD — it has increased 23.08 % in the last trading day.

arrow icon

What is iBio Inc (IBIO)'s business?

iBio, Inc. is a preclinical stage biotechnology company that leverages artificial intelligence (AI) for the development of precision antibodies. The Company develops biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard-to-target cancers and other diseases. Its StableHu technology is an AI-based tool designed to predict a library of antibodies with fully human Complementarity-Determining Region (CDR) variants based on an input antibody. Its pre-clinical pipeline of immuno-oncology targets the treatment of solid tumors, glioblastoma, head, and neck cancers. Its pipeline includes IBIO-101, TROP-2 x CD3, MUC16, EGFRvIII, CCR8, and Target 5. IBIO-101 is an anti-CD25 monoclonal antibody (mAb) that has demonstrated in preclinical models of disease the ability to bind and deplete immunosuppressive regulatory T (Treg) cells to inhibit the growth of solid tumors.

arrow icon

What is the price predicton of IBIO Stock?

Wall Street analysts forecast IBIO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IBIO is 3.90 USD with a low forecast of 1.60 USD and a high forecast of 6.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is iBio Inc (IBIO)'s revenue for the last quarter?

iBio Inc revenue for the last quarter amounts to 100.00K USD, decreased % YoY.

arrow icon

What is iBio Inc (IBIO)'s earnings per share (EPS) for the last quarter?

iBio Inc. EPS for the last quarter amounts to -0.11 USD, decreased -76.09 % YoY.

arrow icon

What changes have occurred in the market's expectations for iBio Inc (IBIO)'s fundamentals?

The market is revising Upward the revenue expectations for iBio, Inc. (IBIO) for FY2026, with the revenue forecasts being adjusted by 80% over the past three months. During the same period, the stock price has changed by 53.29%.
arrow icon

How many employees does iBio Inc (IBIO). have?

iBio Inc (IBIO) has 20 emplpoyees as of December 05 2025.

arrow icon

What is iBio Inc (IBIO) market cap?

Today IBIO has the market capitalization of 29.01M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free